Novan (NOVNW) Pre-Tax Income : $-31.99 Mil (TTM As of Mar. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Novan Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Novan's pretax income for the three months ended in Mar. 2023 was $-14.06 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2023 was $-31.99 Mil. Novan's pretax margin was -469.39%.

During the past 9 years, Novan's highest Pretax Margin was -129.46%. The lowest was -1384.01%. And the median was -687.32%.

Novan Pre-Tax Income Historical Data

The historical data trend for Novan's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novan Pre-Tax Income Chart

Novan Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Pre-Tax Income

Get a 7-Day Free Trial

-29.24

-30.38

-29.29

-29.69

-31.31

Novan Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Pre-Tax Income	Get a 7-Day Free Trial															-13.38	-8.88	-6.03	-3.02	-14.06

Competitive Comparison of Novan's Pre-Tax Income

For the Biotechnology subindustry, Novan's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novan's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novan's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Novan's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Novan Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Novan's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-35.39	+	5.478	+	-1.452	+	0.053	+	-3.5527136788005E-15
	=	-31.31

Novan's Pretax Income for the quarter that ended in Mar. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-13.468	+	-0.348	+	-0.277	+	0.03	+	0
	=	-14.06

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.99 Mil.

Novan (OTCPK:NOVNW) Pre-Tax Income Explanation

Novan's Pretax Margin for the quarter that ended in Mar. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-14.063	/	2.996
	=	-469.39%

During the past 9 years, Novan's highest Pretax Margin was -129.46%. The lowest was -1384.01%. And the median was -687.32%.

Novan Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Novan's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Novan Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novan Inc (OTCPK:NOVNW) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 64, Pittsboro, NC, USA, 27312

Website

https://www.novan.com

NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.